This suggests that, for a subset of patients with less aggressive PCa experiencing biochemical recurrence at PSA levels below 0.5 ng/mL, a cautious approach might be warranted, potentially delaying unnecessary salvage radiation [24]. The gene discussed is KLK3; the disease is posterior cortical atrophy.